The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | FRESCO-2: sex-based subgroup analysis of fruquintinib in pre-treated mCRC
Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain, explores a post-hoc subgroup analysis of the FRESCO-2 study (NCT04322539), examining whether patient sex influences the efficacy and safety of fruquintinib, a selective VEGFR inhibitor, in previously treated metastatic colorectal cancer (mCRC). Fruquintinib improved overall and progression-free survival over placebo in both males and females, with no significant interaction between survival benefit and sex after accounting for differences in subsequent therapy use. Safety findings were generally consistent across sexes, supporting comparable use of fruquintinib regardless of patient sex. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
